The Legacy Project
Who are we?
The HVTN Legacy Project works to increase the participation of people of color in HIV vaccine trials to make sure the vaccine works
for the populations most affected by the virus.
The project also hopes to provide insight on the impact of historic health disparities and comorbidities to HIV risk. In order to build a legacy of trust the Legacy Project fosters partnerships that can impact HIV vaccine clinical trials conduct.
In the struggle to create an HIV vaccine, the products tested have not protected against HIV infection. There have been so few African Americans and Hispanics in the studies that even if the vaccine had shown promise,
scientists would not have been able to know how effective it would be for these racial and ethnic groups. Studies must have enough
representation from each subgroup.
To create an effective vaccine for all people, the types and numbers of HIV vaccine research participants must be based on a formula that reflects each group's
level of risk and HIV infection rates. In studies conducted by the HIV Vaccine Trials Network (HVTN) to date, 30.6 percent of
volunteers were Black and only 5.3 percent were Hispanic. These numbers are not adequate to accurately assess the effectiveness of any
vaccine candidate on these communities.
The Legacy Project's goal is to increase the participation of African Americans and Hispanics in HIV vaccine studies. We are committed to
building bridges of trust to overcome the misinformation that threatens the effective search for a vaccine that could end the AIDS
pandemic. We are committed to building a legacy of trust.
We can be reached at firstname.lastname@example.org